Payment overview · 2025
General Payments
$1,423.33
55 reported records · 10 companies
Healthcare provider profile · identity verified
Jack J Zhou, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HONOLULU, HI · NPI 1265402168
Verified facts
What the public records show
CMS Open Payments records show Jack J Zhou, MD received $1,423.33 in general payments during 2025 across 55 reported records.
ABBVIE INC. accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 314 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $430.11 | 30.2% | 16 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $277.17 | 19.5% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $275.02 | 19.3% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $133.39 | 9.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.24 | 4.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60.95 | 4.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.04 | 4.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.51 | 3.8% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $50.11 | 3.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.79 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,423.33 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $294.15 | 10 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $261.31 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $210.31 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $133.39 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $63.24 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $61.92 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $60.95 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.04 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $53.51 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $50.11 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $40.44 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.10 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.25 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 232 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 107 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 314 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 244 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 167 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 136 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
244 | 51 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
99 | 60 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
107 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
314 | 51 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
107 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
136 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
167 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
232 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2547 | 482 |
| Losartan Potassium | Losartan Potassium | 1874 | 371 |
| Amlodipine Besylate | Amlodipine Besylate | 1302 | 254 |
| Omeprazole | Omeprazole | 921 | 210 |
| Metformin Hcl | Metformin Hcl | 825 | 161 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 789 | 249 |
| Meloxicam | Meloxicam | 681 | 175 |
| Alendronate Sodium | Alendronate Sodium | 671 | 117 |
| Tamsulosin Hcl | Tamsulosin Hcl | 604 | 112 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 571 | 101 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 551 | 115 |
| Metoprolol Succinate | Metoprolol Succinate | 528 | 105 |
| Amoxicillin | Amoxicillin | 525 | 317 |
| Celecoxib | Celecoxib | 468 | 108 |
| Simvastatin | Simvastatin | 439 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 390 | 73 |
| Glipizide | Glipizide | 388 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 376 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 77 |
| Finasteride | Finasteride | 315 | 47 |
| Jardiance | Empagliflozin | 314 | 51 |
| Furosemide | Furosemide | 276 | 66 |
| Famotidine | Famotidine | 261 | 69 |
| Linzess | Linaclotide | 244 | 51 |
| Gabapentin | Gabapentin | 241 | 57 |
| Eliquis | Apixaban | 232 | 47 |
| Carvedilol | Carvedilol | 228 | 42 |
| Clobetasol Propionate | Clobetasol Propionate | 227 | 60 |
| Glipizide Er | Glipizide | 206 | 40 |
| Ranolazine Er | Ranolazine | 206 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 48 |
| Meclizine Hcl | Meclizine Hcl | 195 | 72 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 191 | 35 |
| Atenolol | Atenolol | 189 | 41 |
| Gemfibrozil | Gemfibrozil | 183 | 39 |
| Januvia | Sitagliptin Phosphate | 171 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 167 | 45 |
| Ozempic | Semaglutide | 167 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 155 | 43 |
| Donepezil Hcl | Donepezil Hcl | 138 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 136 | 25 |
| Raloxifene Hcl | Raloxifene Hcl | 135 | 23 |
| Alprazolam | Alprazolam | 133 | 25 |
| Allopurinol | Allopurinol | 131 | 29 |
| Lisinopril | Lisinopril | 127 | 22 |
| Metoclopramide Hcl | Metoclopramide Hcl | 117 | 28 |
| Ezetimibe | Ezetimibe | 116 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 25 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 109 | 15 |
| Farxiga | Dapagliflozin Propanediol | 107 | 25 |
| Vemlidy | Tenofovir Alafenamide | 107 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 106 | 72 |
| Clotrimazole | Clotrimazole | 106 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 100 | 25 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 100 | 29 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 99 | 18 |
| Prolia | Denosumab | 99 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 20 |
| Cephalexin | Cephalexin | 93 | 63 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 29 |
| Pregabalin | Pregabalin | 93 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 91 | 16 |
| Loperamide | Loperamide Hcl | 90 | 49 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 90 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 89 | 18 |
| Procto-Med Hc | Hydrocortisone | 89 | 23 |
| Lovastatin | Lovastatin | 88 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 21 |
| Trazodone Hcl | Trazodone Hcl | 84 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 20 |
| Azithromycin | Azithromycin | 75 | 42 |
| Mirtazapine | Mirtazapine | 69 | 12 |
| Tramadol Hcl | Tramadol Hcl | 68 | 18 |
| Vascepa | Icosapent Ethyl | 68 | 15 |
| Potassium Chloride | Potassium Chloride | 65 | 21 |
| Metformin Hcl Er | Metformin Hcl | 63 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 16 |
| Felodipine Er | Felodipine | 61 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 59 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 58 | 13 |
| Alcohol Pads | Alcohol Antiseptic Pads | 57 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 56 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 54 | 11 |
| Entecavir | Entecavir | 52 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 11 |
| Diazepam | Diazepam | 50 | 12 |
| Nifedipine Er | Nifedipine | 50 | suppressed |
| Trulicity | Dulaglutide | 50 | 15 |
| Hydrocortisone | Hydrocortisone | 49 | 21 |
| Baclofen | Baclofen | 47 | 15 |
| Ibuprofen | Ibuprofen | 46 | 16 |
| Restasis | Cyclosporine | 44 | suppressed |
| Nitroglycerin | Nitroglycerin | 42 | 24 |
| Prednisone | Prednisone | 42 | 28 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 39 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | suppressed |
| Colchicine | Colchicine | 35 | suppressed |
| Naproxen | Naproxen | 35 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Ketoconazole | Ketoconazole | 33 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 32 | suppressed |
| Creon | Lipase/Protease/Amylase | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 22 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Methimazole | Methimazole | 31 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Fluocinonide | Fluocinonide | 24 | 13 |
| Klor-Con 10 | Potassium Chloride | 24 | suppressed |
| Nadolol | Nadolol | 24 | suppressed |
| Propylthiouracil | Propylthiouracil | 24 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | 12 |
| Gentamicin Sulfate | Gentamicin Sulfate | 17 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Alphagan P | Brimonidine Tartrate | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Apriso | Mesalamine | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,423.33 · 55 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CREON, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, LINZESS, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error